B-type natriuretic peptide concentrations and myocardial dysfunction in critical illness

Anaesthesia and Intensive Care

Volumn 34, Issue 2, 2006, Pages 151-163

  Sturges, David J ^a,b   Marwick, T H ^b   Joyce, C J ^a,b   Venkatesh, B ^a,b,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WESLEY HOSPITAL   (Australia)

Author keywords

B type natriuretic peptide; Biological marker; Biomarker; Brain natriuretic peptide; Critical care; Critical illness; Natriuretic peptides; Review

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NATRIURETIC PEPTIDE TYPE C; SEX HORMONE; THYROXINE; TROPONIN I;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; CARDIOVASCULAR DISEASE; CHRONIC LIVER DISEASE; CLEARANCE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CORONARY ARTERY BYPASS GRAFT; CRITICAL ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DYSPNEA; EVIDENCE BASED MEDICINE; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LUNG EMBOLISM; MEDICAL RESEARCH; MYOCARDIAL DISEASE; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PREDICTIVE VALIDITY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN STRUCTURE; REFERENCE VALUE; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDATION STUDY; VALVULAR HEART DISEASE;

EID: 33645758550     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0603400218     Document Type: Review

References (95)

1. Azzazy HM, Christenson RH. B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail Rev 2003; 8:315-320.
2. Venugopal J. Cardiac natriuretic peptides - hope or hype? J Clin Pharm Ther 2001; 26:15-31.
3. Hirose S, Hagiwara H, Takei Y. Comparative molecular biology of natriuretic peptide receptors. Can J Physiol Pharmacol 2001; 79:665-672.
4. Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 1984; 118:131-139.
5. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28:89-94.
6. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81.
7. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195-203.
8. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168:863-870.
9. Matsuo H. Discovery of a natriuretic peptide family and their clinical application. Can J Physiol Pharmacol 2001; 79:736-740.
10. Baxter GF. The natriuretic peptides. Basic Res Cardiol 2004; 99:71-75.
11. Yamamoto K, Burnett JC, Jr., Jougasaki M et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994.
12. Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 2003; 4 Suppl 4:S3-12.
13. Sawada Y, Suda M, Yokoyama H et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997; 272:20545-20554.
14. Nakao K, Mukoyama M, Hosoda K et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991; 69:1500-1506.
15. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6:257-260.
16. Nakagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96:1280-1287.
17. Tenhunen O, Szokodi I, Ruskoaho H. Posttranscriptional activation of BNP gene expression in response to increased left ventricular wall stress: role of calcineurin and PKC. Regul Pept 2005; 128:187-196.
18. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412.
19. Ogawa Y, Itoh H, Tamura N et al. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 1994; 93:1911-1921.
20. Tamura N, Ogawa Y, Chusho H et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000; 97:4239-4244.
21. Maack T, Suzuki M, Almeida FA et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238:675-678.
22. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005; 26:1044-1059.
23. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000; 167:239-246.
24. McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003; 31:2611-2618.
25. Emdin M, Clerico A, Clemenza F et al. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005; 6:430-446.
26. Troughton RW, Richards AM, Yandle TG, Nicholls G. Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure. Circulation 2004; 109: e325-6; author reply e-6.
27. Yancy CW. Practical considerations for BNP use. Heart Fail Rev 2003; 8:369-373.
28. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50:33-50.
29. Epshteyn V, Morrison K, Krishnaswamy P et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003; 26:2081-2087.
30. Asakawa H, Fukui T, Tokunaga K, Kawakami F. Plasma brain natriuretic peptide levels in normotensive Type 2 diabetic patients without cardiac disease and macroalbuminuria. J Diabetes Complications 2002; 16:209-213.
31. Ohsaki Y, Gross AJ, Le PT, Oie H, Johnson BE. Human small cell lung cancer cells produce brain natriuretic peptide. Oncology 1999; 56:155-159.
32. Walter M, Berendes E, Claviez A, Suttorp M. Inappropriate secretion of natriuretic peptides in a patient with a cerebral tumor. JAMA 1999; 282:27-28.
33. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600.
34. Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251:228-234.
35. Snowden JA, Hill GR, Hunt P et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26:309-313.
36. Giannitsis E, Katus HA. Still unresolved issues with brain-type natriuretic peptide measurement in the critically ill patient. Crit Care Med 2003; 31:2703-2704.
37. Clerico A, Prontera C, Emdin M et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 2005; 51:445-447.
38. McLean AS, Tang B, Nalos M, Huang SJ, Stewart DE. Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. Anaesth Intensive Care 2003; 31:21-27.
39. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 2002; 3 Suppl 4:S10-17.
40. Berendes E, Van Aken H, Raufhake C, Schmidt C, Assmann G, Walter M. Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth Analg 2001; 93:676-682.
41. Tung RH, Garcia C, Morss AM et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32:1643-1647.
42. Cuthbertson BH, Patel RR, Croal BL, Barclay J, Hillis GS. B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia 2005; 60:16-21.
43. Dokainish H, Zoghbi WA, Lakkis NM et al. Optimal non-invasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109:2432-2439.
44. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 2004; 125:652-668.
45. Knudsen CW, Riis JS, Finsen AV et al. Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender. Eur J Heart Fail 2004; 6:55-62.
46. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
47. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003; 4 Suppl 4: S13-9.
48. Prahash A, Lynch T. B-type natriuretic peptide: a diagnostic, prognostic, and therapeutic tool in heart failure. Am J Crit Care 2004; 13:46-53; quiz 4-5.
49. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509-516.
50. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105:2392-2397.
51. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37:386-391.
52. Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278-1283.
53. Ishii J, Nomura M, Nakamura Y et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002; 89:691-695.
54. Fonarow GC, Horwich TB. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. Rev Cardiovasc Med 2003; 4 Suppl 4:S20-28.
55. Ishii J, Cui W, Kitagawa F et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 2003; 49:2020-2026.
56. Sodian R, Loebe M, Schmitt C et al. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol 2001; 38:1942-1949.
57. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995; 88:551-556.
58. de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev Cardiovasc Med 2003; 4 Suppl 4:S37-46.
59. Omland T, Aakvaag A, Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93:1963-1969.
60. Richards AM, Nicholls MG, Espiner EA et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107:2786-2792.
61. Richards AM, Nicholls MG, Yandle TG et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 1999; 81:114-120.
62. Arakawa N, Nakamura M, Endo H, Sugawara S, Suzuki T, Hiramori K. Brain natriuretic peptide and cardiac rupture after acute myocardial infarction. Intern Med 2001; 40:232-236.
63. Omland T, de Lemos JA, Morrow DA et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89:463-465.
64. Morrow DA, de Lemos JA, Sabatine MS et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41:1264-1272.
65. Terazawa E, Dohi S, Akamastsu S, Ohata H, Shimonaka H. Changes in calcitonin gene-related peptide, atrial natriuretic peptide and brain natriuretic peptide in patients undergoing coronary artery bypass grafting. Anaesthesia 2003; 58:223-232.
66. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999; 100:287-291.
67. Hervas I, Almenar L, Perez-Pastor JL et al. Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determinations and biopsy grading of rejection. Nucl Med Commun 2003; 24:925-931.
68. Gerber IL, Stewart RA, French JK et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 2003; 92:755-758.
69. Fukuda N, Shinohara H, Sakabe K, Nada T, Tamura Y. Plasma levels of brain natriuretic peptide in various forms of obstruction to the left ventricular outflow tract. J Heart Valve Dis 2003; 12:333-340.
70. Sutton TM, Stewart RA, Gerber IL et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003; 41:2280-2287.
71. Kelly CA, Newby DE, McDonagh TA et al. Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J 2002; 23:1379-1386.
72. Thorens JB, Ritz M, Reynard C et al. Haemodynamic and endocrinological effects of noninvasive mechanical ventilation in respiratory failure. Eur Respir J 1997; 10:2553-2559.
73. Kruger S, Graf J, Merx MW et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147:60-65.
74. Bilkovski RN, Kulstad EB. Elevations of B-type natriuretic peptide in pulmonary embolism: a case series. J Emerg Med 2003; 25:415-420.
75. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545-2547.
76. ten Wolde M, Tulevski II, Mulder JW et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107:2082-2084.
77. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Itoh M, Amaha K. Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care 1997; 12:66-71.
78. Maeder M, Ammann P, Rickli H, Diethelm M. Elevation of B-type natriuretic peptide levels in acute respiratory distress syndrome. Swiss Med Wkly 2003; 133:515-518.
79. Charpentier J, Luyt CE, Fulla Y et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32:660-665.
80. Witthaut R, Busch C, Fraunberger P et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29:1696-1702.
81. Espiner EA, Leikis R, Ferch RD et al. The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2002; 56:629-635.
82. Parekh N, Venkatesh B, Cross D et al. Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. J Am Coll Cardiol 2000; 36:1328-1335.
83. Balik M, Jabor A, Kolar M et al. Relationship between natriuretic peptides and residual diuresis during continuous hemodiafiltration. Blood Purif 2003; 21:401-408.
84. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52:1511-1517.
85. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 2001; 101:621-628.
86. Bellomo R, Uchino S. Cardiovascular monitoring tools: use and misuse. Curr Opin Crit Care 2003; 9:225-229.
87. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 2004; 10:336-341.
88. Jensen KT, Carstens J, Ivarsen P, Pedersen EB. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997; 57:529-540.
89. Kanda H, Kita Y, Okamura T et al. What factors are associated with high plasma B-type natriuretic peptide levels in a general Japanese population? J Hum Hypertens 2005; 19:165-172.
90. Kjaer A, Appel J, Hildebrandt P, Petersen CL. Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects. Eur J Heart Fail 2004; 6:29-39.
91. Mottram PM, Haluska BA, Marwick TH. Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: correlation with cardiac function, hemodynamics, and workload. Am Heart J 2004; 148:365-370.
92. Margulies KB, Jaffer S, Pollack PS, Ennis KJ. Physiological significance of early deceleration time prolongation in asymptomatic elderly subjects. J Card Fail 1999; 5:92-99.
93. Wilkins MA, Su XL, Palayew MD et al. The effects of posture change and continuous positive airway pressure on cardiac natriuretic peptides in congestive heart failure. Chest 1995; 107:909-915.
94. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41:571-579.
95. Davis M, Espiner E, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343:440-444.